Zion Market Research has published a new report titled “Hepatitis C Drug Market for Hospitals, Private labs, Physician offices, Public health labs and Blood banks – Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022.” According to the report, the global Hepatitis C drug market accounted for around USD 13.50 billion in 2016 and is expected to reach approximately USD 33.50 by 2022, growing at a CAGR of around 16.0% between 2017 and 2022.
Hepatitis C virus is a small (55 to 65 nm), spherical, enveloped, hepatotropic RNA virus that causes acute and chronic hepatitis in humans. Persistent virus infection with HCV often leads to cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that a minimum of 3 percent of the world’s population is chronically infected with HCV. HCV is most commonly spread by direct contact with infected blood and blood products. Availability of injectable therapies and drugs has had a remarkable influence on HCV epidemiology. The incubation period of HCV, though ranging up to several months, averages 6-8 weeks.
Request Free Sample copy of Research Report @ https://www.zionmarketresearch.com/sample/hepatitis-c-drug-market
Hepatitis C is a serious liver disease that is caused as a result of infection with the hepatitis C virus. From a long time, hepatitis C has been called a silent disease because people can get infected and not know it for years. Some people who get infected with hepatitis C virus are able to clear or get rid of the virus, but most people who get infected develop a chronic, or lifelong, infection. Over time, chronic hepatitis C can cause serious health problems including liver damage, liver failure, and even liver cancer.
Globally, hepatitis C drug market has been accelerated due to the continuous rise in the percentage of hepatitis C infections among individuals. Furthermore, lack of awareness is considered as a major key factor which is expected to promote the growth of hepatitis C drug market. Moreover, many lifestyle-related factors, such as unprotected sex, unhygienic precautions by the medical institution can also promote the hepatitis C infection. In addition, rising government funding coupled with a smaller period of treatment are likely to fuel the growth of hepatitis C drug market. However, the high cost of drugs coupled with threat-related to regulation and development of the drug is a key restraining factor for the growth of hepatitis C drug market. Nonetheless, ongoing research and upcoming new efficient therapies are expected to bring growth avenues in nearby future.
Browse the full “Hepatitis C Drug Market for Hospitals, Private labs, Physician Offices, Public Health Labs and Blood Banks – Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022 ” report at https://www.zionmarketresearch.com/report/hepatitis-c-drug-market
On the basis of end-users, hepatitis C drug market is segmented into five types: hospitals, private labs, physician offices, public health labs and blood banks. These segments are the key end-users of hepatitis C drug market. Among all, hospital and labs are the major segments and are expected to be the fastest growing applications in forthcoming years.
On the basis of geographical regions, the global hepatitis C drug market is segmented into five regions which include North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into the U.S., U.K., Germany, France, China, Japan, India, and Brazil. North America was the largest regional market for hepatitis C drugs in 2016. In this region, the U.S. was the largest revenue contributor for global hepatitis C drug market. Further, it is expected to continue this trend during near future owing to ongoing research and development in pharmaceutical industry. Europe was the second largest market for hepatitis C drugs. Further, demand for hepatitis C drug is increasing in Asia-Pacific, Latin America, and Middle East & Africa region due to the prevalence of the disease in these regions coupled with increasing expenditure on healthcare infrastructure over the years to come.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/hepatitis-c-drug-market
Major key players in the global hepatitis C drug market include Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
4283, Express Lane,
Sarasota, Florida 34249, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651